Parkinsonism & related disorders · 2025
CSF markers of neuroinflammation, synaptic dysfunction and [18F]DOPA-PET in Parkinson's disease.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hauer Kevin Oliveira, Hall Sara, Nahimi Adjmal, Strandberg Olof, Ohlsson Tomas, Jögi Jonas, Stomrud Erik, Janelidze Shorena, Hansson Oskar, Smith Ruben
Аннотация
INTRODUCTION: Neuromelanin containing cell loss, neuroinflammation and synaptic dysfunction are believed to contribute to Parkinson's disease (PD) pathogenesis. [18F]DOPA PET reflects dopamine storage capacity in the putamen, while midbrain off-target retention of [18F]RO948 is hypothesized to reflect neuromelanin.
OBJECTIVES: To investigate associations between disease duration, cerebrospinal fluid (CSF) markers of neurodegeneration, synaptic dysfunction, neuroinflammation, and dopamine synaptic loss as measured by [18F]DOPA PET in PD patients. We further aimed to explore whether reduced midbrain retention of [18F]RO948 relates to [18F]DOPA PET and CSF markers.
METHODS: Participants were part of the BioFINDER studies. CSF biomarkers were analyzed for controls (n = 623), PD participants (n = 226) and Dementia with Lewy bodies (DLB; n = 33). [18F]RO948 PET was performed in controls (n = 514), PD (n = 77) and DLB (n = 47) and [18F]DOPA PET in PD (n = 58) and DLB (n = 22).
RESULTS: PD patients showed higher CSF neurofilament light (NfL) levels (pg/ml [mean ± SD] 159 ± 139) vs. controls (137 ± 90, p < 0.001), and lower neurogranin (pg/ml [mean ± SD] 620 ± 255) vs (772 ± 283, p < 0.001). Lower [18F]DOPA uptake correlated with longer disease duration (ρ = -0.46, p < 0.001), higher NfL (ρ = -0.39, p = 0.03), lower neurogranin (ρ = 0.50, p = 0.003) and NPTX2 levels (ρ = 0.36, p = 0.049). We found no associations between neuroinflammatory markers and [18F]DOPA PET. Substantia nigra [18F]RO948 signal was lower in PD ([mean ± SD] 1.67 ± 0.22) vs controls (1.76 ± 0.3, p < 0.001) but did not correlate with disease duration, CSF markers or [18F]DOPA-PET.
CONCLUSIONS: In PD patients, a decrease in [18F]DOPA PET retention correlated with disease duration as well as CSF neurodegenerative and synaptic biomarkers but not with inflammatory biomarkers or [18F]RO948 PET midbrain off-target retention.
OBJECTIVES: To investigate associations between disease duration, cerebrospinal fluid (CSF) markers of neurodegeneration, synaptic dysfunction, neuroinflammation, and dopamine synaptic loss as measured by [18F]DOPA PET in PD patients. We further aimed to explore whether reduced midbrain retention of [18F]RO948 relates to [18F]DOPA PET and CSF markers.
METHODS: Participants were part of the BioFINDER studies. CSF biomarkers were analyzed for controls (n = 623), PD participants (n = 226) and Dementia with Lewy bodies (DLB; n = 33). [18F]RO948 PET was performed in controls (n = 514), PD (n = 77) and DLB (n = 47) and [18F]DOPA PET in PD (n = 58) and DLB (n = 22).
RESULTS: PD patients showed higher CSF neurofilament light (NfL) levels (pg/ml [mean ± SD] 159 ± 139) vs. controls (137 ± 90, p < 0.001), and lower neurogranin (pg/ml [mean ± SD] 620 ± 255) vs (772 ± 283, p < 0.001). Lower [18F]DOPA uptake correlated with longer disease duration (ρ = -0.46, p < 0.001), higher NfL (ρ = -0.39, p = 0.03), lower neurogranin (ρ = 0.50, p = 0.003) and NPTX2 levels (ρ = 0.36, p = 0.049). We found no associations between neuroinflammatory markers and [18F]DOPA PET. Substantia nigra [18F]RO948 signal was lower in PD ([mean ± SD] 1.67 ± 0.22) vs controls (1.76 ± 0.3, p < 0.001) but did not correlate with disease duration, CSF markers or [18F]DOPA-PET.
CONCLUSIONS: In PD patients, a decrease in [18F]DOPA PET retention correlated with disease duration as well as CSF neurodegenerative and synaptic biomarkers but not with inflammatory biomarkers or [18F]RO948 PET midbrain off-target retention.